Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 14/20 | 0.47 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.45 |
| ▸ | STK17B | O94768 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4248304 | 0.78 | APP (0.49) | APPEGFRMAPK3MAPK1MAP2K1 | |
| SCHEMBL30727703 | 0.76 | QPCT (0.39) | — | |
| SCHEMBL17167476 | 0.71 | APP (0.59) | APPMAPK3MAPK1MAP2K1 | |
| SCHEMBL22479140 | 0.71 | HSP90AA1 (0.46) | APPMAPK1POLB | |
| SCHEMBL20406217 | 0.71 | POLB (0.50) | APPPOLB | |
| SCHEMBL7054718 | 0.70 | MAP3K8 (0.62) | MAP2K1 | |
| SCHEMBL27771625 | 0.70 | APP (0.58) | APPEGFR | |
| SCHEMBL793498 | 0.69 | ALDH1A1 (0.45) | APP | |
| SCHEMBL2541138 | 0.69 | HSP90AA1 (0.47) | POLB | |
| SCHEMBL441078 | 0.69 | ALDH1A1 (0.39) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2043654-A2 | THIENOPYRIMIDINES USEFUL AS MODULATORS OF ION CHANNELS | Vertex Pharmaceuticals, Inc. (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2007146284-A2 | THIENOPYRIMIDINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-12-21 | — | — | WO | disclosed |